Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Denis Smith

Showing results (51-60 of 96) with videos related to

Pageof 10
Sort By:
Clinical Colorectal Cancer|March 11, 2018
Effectiveness of Cetuximab as First-Line Therapy for Patients With Wild-Type KRAS and Unresectable Metastatic Colorectal Cancer in Real-Life Practice: Results of the EREBUS CohortMagali Rouyer, Eric François, Antonio Sa Cunha, et al.
Advances in Therapy|April 14, 2022
Observational Study in a Real-World Setting of Targeted Therapy in the Systemic Treatment of Progressive Unresectable or Metastatic Well-Differentiated Pancreatic Neuroendocrine Tumors (pNETs) in France: OPALINE StudyDenis Smith, Côme Lepage, Eric Vicaut, et al.
British Journal of Cancer|August 18, 2017
Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228)Francis Lévi, Abdoulaye Karaboué, Raphaël Saffroy, et al.
Acta Oncologica (Stockholm, Sweden)|July 1, 2021
Neoadjuvant treatment for borderline resectable pancreatic adenocarcinoma is associated with higher R0 rate compared to upfront surgeryMario Terlizzi, Etienne Buscail, Olayidé Boussari, et al.
Oncotarget|April 29, 2015
Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the "THERAPY"phase 1-2 trialEric Assenat, David Azria, Caroline Mollevi, et al.
Clinics and Research in Hepatology and Gastroenterology|April 29, 2019
Characteristic and outcomes of patients with pathologic complete response after preoperative treatment in borderline and locally advanced pancreatic adenocarcinoma: An AGEO multicentric retrospective cohortHampig Kourie, Edouard Auclin, Antonio Sa Cunha, et al.
Gastroenterologie Clinique Et Biologique|September 6, 2005
Value of microsatellite instability typing in detecting hereditary non-polyposis colorectal cancer. A prospective multicentric study by the Association Aquitaine GastroYves Bécouarn, Anne Rullier, Philippe Gorry, et al.
Clinical Pharmacokinetics|June 18, 2016
Bevacizumab Pharmacokinetics Influence Overall and Progression-Free Survival in Metastatic Colorectal Cancer PatientsMorgane Caulet, Thierry Lecomte, Olivier Bouché, et al.
Therapeutic Advances in Medical Oncology|November 20, 2024
SUNLAND: a randomized, double-blinded phase II GERCOR trial of sunitinib versus placebo and lanreotide in patients with advanced progressive midgut neuroendocrine tumorsPascal Hammel, Denis Smith, Pauline Afchain, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|January 14, 2022
Phase III randomized trial comparing systemic versus intra-arterial oxaliplatin, combined with LV5FU2 +/- irinotecan and a targeted therapy, in the first-line treatment of metastatic colorectal cancer restricted to the liver (OSCAR): PRODIGE 49Simon Pernot, Olivier Pellerin, Laurent Mineur, et al.
Pageof 10

Showing results (51-60 of 96) with videos related to

Sort By:
Pageof 10
Clinical Colorectal Cancer|March 11, 2018
Effectiveness of Cetuximab as First-Line Therapy for Patients With Wild-Type KRAS and Unresectable Metastatic Colorectal Cancer in Real-Life Practice: Results of the EREBUS CohortMagali Rouyer, Eric François, Antonio Sa Cunha, et al.
Advances in Therapy|April 14, 2022
Observational Study in a Real-World Setting of Targeted Therapy in the Systemic Treatment of Progressive Unresectable or Metastatic Well-Differentiated Pancreatic Neuroendocrine Tumors (pNETs) in France: OPALINE StudyDenis Smith, Côme Lepage, Eric Vicaut, et al.
British Journal of Cancer|August 18, 2017
Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228)Francis Lévi, Abdoulaye Karaboué, Raphaël Saffroy, et al.
Acta Oncologica (Stockholm, Sweden)|July 1, 2021
Neoadjuvant treatment for borderline resectable pancreatic adenocarcinoma is associated with higher R0 rate compared to upfront surgeryMario Terlizzi, Etienne Buscail, Olayidé Boussari, et al.
Oncotarget|April 29, 2015
Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the "THERAPY"phase 1-2 trialEric Assenat, David Azria, Caroline Mollevi, et al.
Clinics and Research in Hepatology and Gastroenterology|April 29, 2019
Characteristic and outcomes of patients with pathologic complete response after preoperative treatment in borderline and locally advanced pancreatic adenocarcinoma: An AGEO multicentric retrospective cohortHampig Kourie, Edouard Auclin, Antonio Sa Cunha, et al.
Gastroenterologie Clinique Et Biologique|September 6, 2005
Value of microsatellite instability typing in detecting hereditary non-polyposis colorectal cancer. A prospective multicentric study by the Association Aquitaine GastroYves Bécouarn, Anne Rullier, Philippe Gorry, et al.
Clinical Pharmacokinetics|June 18, 2016
Bevacizumab Pharmacokinetics Influence Overall and Progression-Free Survival in Metastatic Colorectal Cancer PatientsMorgane Caulet, Thierry Lecomte, Olivier Bouché, et al.
Therapeutic Advances in Medical Oncology|November 20, 2024
SUNLAND: a randomized, double-blinded phase II GERCOR trial of sunitinib versus placebo and lanreotide in patients with advanced progressive midgut neuroendocrine tumorsPascal Hammel, Denis Smith, Pauline Afchain, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|January 14, 2022
Phase III randomized trial comparing systemic versus intra-arterial oxaliplatin, combined with LV5FU2 +/- irinotecan and a targeted therapy, in the first-line treatment of metastatic colorectal cancer restricted to the liver (OSCAR): PRODIGE 49Simon Pernot, Olivier Pellerin, Laurent Mineur, et al.
Pageof 10